Ematoncologia

With the recent discovery of JAK2 mutations in myeloproliferative disorders, medical science has taken a revolutionary stride forward toward understanding the pathogenesis of these diseases. This new advancement translates not only to a more rapid and reliable diagnosis, but also allows groundbreaking research into the development of new therapeutics. Written in an easy-to-follow text "Myeloproliferative Disorders" gives the practicing clinician a single source answer to classification, diagnosis, management, and recent advances in this disorder.

Multiple myeloma is the second most prevalent hematological malignancy, with over 55,000 new cases diagnosed each year. This exciting new text, edited by lauded authorities on the topic, stands as the only available reference to assemble, review, and synthesizes the latest studies on translational therapies and clearly explains the impact of molecular pathogenesis, biology, and prognostic factors on the diagnosis, prognosis, and individualization of treatment and the development of novel therapeutic options for patients with myeloma. Moving from the bench to the bedside to the forefront of therapeutic development, this source: helps clinicians and researchers effectively deploy therapeutic strategies into clinical practice reflects trends in the use of agents which target both the tumor cell and its bone marrow microenvironment to overcome resistance to conventional therapies considers the critical role of the bone marrow microenvironment in the regulation of growth, survival, and homing of multiple myeloma discusses novel therapies in phase I and phase II trials, focusing specifically on therapeutic options for patients with newly diagnosed or relapsed/refractory multiple myeloma addresses novel therapies for other plasma cell disorders, and provides the framework for the design of next generation agents and combination therapies covers the entire scope of translational work in multiple myeloma, from advances in molecular pathogenesis, to prognostic factors, immunotherapy, and new options for newly diagnosed and relapsed multiple myeloma patients

The major features of sickle cell disease in most patients are life-long anemia and the recurrent vaso-occlusion. The pathophysiology of sickle cell disease and hemoglobinopathies, along with the diagnosis and assessment of the risk/benefit ration for particular treatments are discussed.

Myelodysplastic Syndromes was first published in 2006, and continues to stand out as the definitive text on the genetics, pathophysiology, and clinical management of this wide range of syndromes. It remains a major reference on all aspects of the clinical classification underlying pathogenetic mechanisms and treatment of the myelodysplastic syndromes. Authored by international experts, the book provides an assessment of the subject's status and a variety of advances in the field. The chapters cover all aspects of the myelodysplastic syndromes, from an in-depth analysis of the multifactorial nature of this disease, including a careful assessment of stromal, immunological and stem cell abnormalities, to a review of recent molecular and cytogenetic discoveries and insights. This book will be a valuable resource to clinicians and researchers who wish to learn more about myelodysplastic syndromes.

The full spectrum of central nervous system lymphoma is covered from patheology and genetics to clinical features, diagnosis and treatment. Also explored are new approaches to therapy and unusual variants of central nervous system lymphoma.

This is the first prize winner in Haematology category of British Medical Association Medical Book Awards 2004! Completely revised and updated, the "3rd Edition" of this premier resource provides cutting-edge coverage of the epidemiology, immunology, and haematology of myeloma - all in one convenient reference. A team of leading international authorities in myeloma research present a worldwide perspective on the most recent developments in management and therapeutic options, as well as the latest clinical understanding of the disease.

With extreme accessibility and a practical clinical approach, "Clinical Practice of Hematology and Oncology" fills the niche of a comprehensive yet concise haematology and oncology resource. Its readability, practical information and applicable clinical tips add to its usefulness as it systematically and concisely covers many major topics in depth with the authority and knowledge of a classic in the making.

Anemia is a frequent complication of cancer and its treatment. A number of clinical studies shows that the impact of anemia is much greater than previously thought. Beyond clinical symptoms, anemia significantly impairs physical and metabolic functions as well as patients' activity, well-being and quality of life. Life expectancy is also affected. In this book, written by a group of outstanding international experts, the current knowledge on anemia in cancer and its treatment with rhEPO is presented and future developments are discussed. Based on a broad spectrum of topics, the book describes the scientific and clinical aspects of anemia in various fields of oncology and gives diagnostic and therapeutic recommendations on when and how to use rhEPO. The book will serve as an authentic and essential source of information for radiotherapists, oncologists, hematologists, internists, pediatricians, surgeons, specialists in transfusion or laboratory medicine and pharmacologists.